Biologic Use in Hidradenitis Suppurativa

Medically reviewed on 6.15.2024 by the PA/NP EMERGE Advisory Board

Bari Genoa, PA-C, MPAS, provides a nuanced portrait of biologic therapies for Hidradenitis Suppurativa (HS). She highlights the effectiveness of adalimumab and secukinumab for moderate to severe cases and explains the importance of early intervention to manage symptoms, reduce lesion recurrence, and prevent disease progression.